Mechanisms of Granulocytopoiesis Recovery Stimulation with Filgrastim in Breast Cancer Patients Receiving Chemotherapy


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅存取

详细

We studied myelotoxicity of modern schemes of chemotherapy for breast cancer (docetaxel/doxorubicin and cyclophosphamide/doxorubicin/5-fluorouracil) towards granulocytopoiesis, the mechanisms determining the differences of hematological effects of these schemes, and the efficiency of correction of the observed changes with granulocyte CSF (filgrastim). Granulocytopoiesis stimulation with filgrastim during the treatment with docetaxel/doxorubicin combination was more pronounced than during cyclophosphamide/doxorubicin/5-fluorouracil therapy. The observed differences were found at all levels of granulocyte lineage organization (central and peripheral), which is related to different effects of the cytostatic substances used in the proposed protocols on the structures controlling hemopoiesis.

作者简介

V. Goldberg

Research Institute of Oncology, Tomsk Research Medical Center of the Russian Academy of Sciences

编辑信件的主要联系方式.
Email: center@tnimc.ru
俄罗斯联邦, Tomsk

T. Polyakova

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk Research Medical Center of the Russian Academy of Sciences; National Research Tomsk State University

Email: center@tnimc.ru
俄罗斯联邦, Tomsk; Tomsk

N. Popova

Research Institute of Oncology, Tomsk Research Medical Center of the Russian Academy of Sciences

Email: center@tnimc.ru
俄罗斯联邦, Tomsk

V. Vysotskaya

Research Institute of Oncology, Tomsk Research Medical Center of the Russian Academy of Sciences

Email: center@tnimc.ru
俄罗斯联邦, Tomsk

E. Simolina

Research Institute of Oncology, Tomsk Research Medical Center of the Russian Academy of Sciences

Email: center@tnimc.ru
俄罗斯联邦, Tomsk

E. Dudnikova

Research Institute of Oncology, Tomsk Research Medical Center of the Russian Academy of Sciences

Email: center@tnimc.ru
俄罗斯联邦, Tomsk

N. Goncharova

Research Institute of Oncology, Tomsk Research Medical Center of the Russian Academy of Sciences

Email: center@tnimc.ru
俄罗斯联邦, Tomsk

Yu. Belevich

Research Institute of Oncology, Tomsk Research Medical Center of the Russian Academy of Sciences

Email: center@tnimc.ru
俄罗斯联邦, Tomsk

T. Tuzikova

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk Research Medical Center of the Russian Academy of Sciences

Email: center@tnimc.ru
俄罗斯联邦, Tomsk

A. Goldberg

Research Institute of Oncology, Tomsk Research Medical Center of the Russian Academy of Sciences

Email: center@tnimc.ru
俄罗斯联邦, Tomsk

L. Miroshnichenko

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk Research Medical Center of the Russian Academy of Sciences

Email: center@tnimc.ru
俄罗斯联邦, Tomsk

E. Udut

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk Research Medical Center of the Russian Academy of Sciences

Email: center@tnimc.ru
俄罗斯联邦, Tomsk

E. Simanina

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk Research Medical Center of the Russian Academy of Sciences

Email: center@tnimc.ru
俄罗斯联邦, Tomsk

G. Zyuz’kov

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk Research Medical Center of the Russian Academy of Sciences

Email: center@tnimc.ru
俄罗斯联邦, Tomsk

V. Zhdanov

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk Research Medical Center of the Russian Academy of Sciences

Email: center@tnimc.ru
俄罗斯联邦, Tomsk

A. Dygai

Research Institute of Oncology, Tomsk Research Medical Center of the Russian Academy of Sciences

Email: center@tnimc.ru
俄罗斯联邦, Tomsk


版权所有 © Springer Science+Business Media, LLC, part of Springer Nature, 2018
##common.cookie##